TYRA
Tyra Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$28.65
+15.25%Aug 4, 2026, 20:05 UTC
Tyra Biosciences appointed Jonathan Day as EVP, Clinical Development to advance its skeletal dysplasia strategy.
Source:Aug 4, 2026, 20:05 UTC
Tyra Biosciences reported financial results for the second quarter ended June 30, 2026, with cash, cash equivalents and marketable securities of $353.9 million and a runway into the second half of 2028.
Source: